multiple sclerosis: A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
3365 |
4. Check minimum number of eventsNone |
3365 |
5. Include endpointsNone |
3365 |
6. Filter based on genotype QC (FinnGen only) |
3047 |
Control definitions (FinnGen only)
- Control exclude
- G6_DISSOTH, G6_OTHDEMYEL, G6_ADEM, G6_ENCEPHBACT, G6_ENCEPHOTH
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G35-G37
- Name in latin
- Sclerosis multiplex
Similar endpoints
↥List of similar endpoints to
MS-disease / Multiple Sclerosis
based on the number of shared cases.
Similar with more cases:
- Demyelinating diseases of the central nervous system
- Autoimmune diseases related-to ILD
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Neurological diseases
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 19836 | 13288 | 6385 |
| Only index persons | 17256 | 11971 | 5285 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.31 | 0.38 | 0.18 |
| Only index persons | 0.37 | 0.44 | 0.20 |
| Median age at first event (years) | |||
| Whole population | 39.19 | 38.69 | 40.18 |
| Only index persons | 38.41 | 38.12 | 39.08 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 3047 | 2290 | 757 |
| Unadjusted period prevalence (%) | 0.70 | 0.81 | 0.35 |
| Median age at first event (years) | 38.17 | 37.15 | 41.25 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 3198
- Matched controls
- 31980
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N06BA07
ATC
modafinil; oral
46.1
317.0
187
43
M03BX01
ATC
baclofen; systemic
31.6
307.7
553
210
XKD06
NOMESCO Finland
Physiologic investigation of micturition
17.6
307.7
373
238
L03AB07
ATC
interferon beta-1a; parenteral
+∞
307.7
965
*
L04AX07
ATC
dimethyl fumarate; oral
+∞
307.7
613
*
N86
ICPC
Multiple sclerosis
2538.5
307.7
1015
6
XCK00
NOMESCO Finland
Perimetry
9.0
307.7
482
618
G35
ICD-10 Finland
Multiple sclerosis
4503599627370496.0
307.7
3116
5
109
Kela drug reimbursment
Multiple sclerosis
+∞
307.7
2201
*
L03AB08
ATC
interferon beta-1b; parenteral
+∞
307.7
417
*
L03AX13
ATC
glatiramer acetate; parenteral
+∞
307.7
771
*
2AB04, ,
NOMESCO Finland
224.0
307.7
248
12
N07XX09
ATC
[U] dimethyl fumarate
+∞
307.7
366
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
32.2
307.7
361
126
G04BD12
ATC
mirabegron; oral
5.9
307.7
694
1426
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
17.9
307.7
375
236
H46
ICD-10 Finland
Optic neuritis
181.9
307.7
815
60
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
22.6
307.7
1634
1411
G04BD09
ATC
trospium; oral
18.3
307.7
307
185
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
15.4
307.7
308
220
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
307.7
1779
*
TAB00
NOMESCO Finland
Lumbar puncture
24.1
307.7
1050
635
L04AA31
ATC
[U] teriflunomide
+∞
307.7
462
*
353
Kela drug reimbursment
Cladribine and fingolimod
+∞
307.7
478
*
XA800
NOMESCO Finland
Neuropsychological investigation
11.4
307.7
552
577
L04AA27
ATC
[U] fingolimod
+∞
307.7
368
*
164
Kela drug reimbursment
Fingolimod
+∞
307.7
531
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
6238.7
307.7
926
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
11.1
307.7
404
412
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
+∞
307.7
1889
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
7.0
307.7
895
1687
N04BB01
ATC
amantadine; oral
66.6
307.7
620
115
R20.2
ICD-10 Finland
Paraesthesia of skin
5.5
295.8
660
1432
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
31.3
283.5
186
63
XKD00
NOMESCO Finland
Uroflowmetry
5.5
274.2
604
1291
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
6.3
268.6
501
916
ZX120
NOMESCO Finland
Intravenous
5.3
267.1
620
1386
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.1
259.1
625
1442
XKC03
NOMESCO Finland
Water cystometry
10.6
245.2
278
284
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
18.2
241.8
197
115
G04BD04
ATC
oxybutynin; oral, transdermal
7.4
240.9
371
554
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
20.4
233.7
180
93
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
+∞
232.2
220
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.7
229.4
938
3191
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
228.9
217
*
L04AG12
ATC
ofatumumab; parenteral
+∞
224.7
213
*
R1250
NOMESCO Finland
Evaluation of functional capability
9.6
215.1
263
297
TKC22
NOMESCO Finland
Catheterisation instruction
14.7
213.8
195
141
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
+∞
211.9
201
*
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
26.9
209.1
144
56
L04AK02
ATC
teriflunomide; oral
+∞
201.2
191
*
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
8.7
200.9
265
329
N03AE01
ATC
clonazepam; systemic
5.5
195.1
409
826
UKC02
NOMESCO Finland
Cystoscopy
4.0
183.6
610
1776
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
4.5
182.4
495
1239
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
182.0
173
*
G04BD07
ATC
tolterodine; oral
7.0
181.4
290
448
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
10.3
177.0
202
207
H53.2
ICD-10 Finland
Diplopia
7.5
175.3
263
379
G04BD08
ATC
solifenacin; oral
5.7
171.9
343
660
34099
ICD-8 Finland
Multiple sclerosis
+∞
167.2
159
*
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
36.3
163.1
102
29
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
19.7
162.9
127
67
N03AX12
ATC
[U] gabapentin; oral
3.2
161.1
792
2955
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
56.5
155.9
88
16
N28
ICPC
Limited function/disability (N)
11.6
147.9
155
140
L04AE01
ATC
fingolimod; oral
+∞
144.9
138
*
L04AA40
ATC
cladribine; oral
+∞
143.8
137
*
4AA23, ,
NOMESCO Finland
1354.8
134.4
130
*
R4150
NOMESCO Finland
Neuropsychological rehabilitation
15.0
133.6
119
82
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.5
133.3
356
872
H02AB04
ATC
methylprednisolone; systemic
3.1
131.7
683
2600
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
13.1
127.7
123
97
SPAT1229
SPAT
Assessment of need for aid
4.6
127.0
329
786
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
70.5
126.8
69
10
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
123.7
118
*
N29
ICPC
Neurological sympt/complt other
8.2
121.8
166
213
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
119.5
114
*
G04BD11
ATC
fesoterodine; oral
8.4
117.8
157
196
L28
ICPC
Limited function/disability (L)
2.9
114.7
665
2674
R33
ICD-10 Finland
Retention of urine
4.7
114.7
282
645
R35
ICD-10 Finland
Polyuria
4.3
114.6
316
791
N99
ICPC
Neurological disease other
11.2
114.3
122
113
XCD10
NOMESCO Finland
Electrophysiological examination of eye
7.7
109.8
157
213
XKD03
NOMESCO Finland
Urethral pressure profilometry
8.0
109.7
151
196
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
10.3
109.6
124
125
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
5.9
108.5
203
365
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
7.8
104.7
148
198
Z2445
NOMESCO Finland
Psychologist
4.4
103.0
271
653
H47.2
ICD-10 Finland
Optic atrophy
24.7
98.8
70
29
XCW99
NOMESCO Finland
Other investigative procedure of eye
3.3
96.7
416
1403
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
20.7
96.1
73
36
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
18.3
93.3
75
42
TKC20
NOMESCO Finland
Catheterisation of bladder
4.1
91.8
265
684
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
10.2
90.8
103
104
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
30.0
89.2
59
20
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.1
88.3
255
658
J01EA01
ATC
trimethoprim; systemic
2.2
86.5
1025
5642
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.2
84.3
365
1232
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.3
84.1
231
574
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
11.6
83.9
87
77
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.5
82.5
638
2919
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
14.2
81.9
75
54
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
5.0
81.7
181
378
SPAT1231
SPAT
Assessment of adjustments needed in living environment
9.2
79.9
98
110
C10AC01
ATC
colestyramine; oral
5.0
79.8
176
366
N03AX16
ATC
[U] pregabalin
2.2
79.7
842
4403
Z3226
NOMESCO Finland
Physiotherapist
2.4
79.5
678
3236
R4120
NOMESCO Finland
Occupational therapy
3.3
79.5
319
1027
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.5
78.8
568
2510
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
10.5
78.5
87
85
Z3231
NOMESCO Finland
Registered nurse
2.2
78.0
948
5233
L04AX01
ATC
azathioprine; systemic
3.9
76.4
240
657
R5110, ,
SPAT
3.2
75.8
330
1115
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.0
75.2
362
1296
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
5.6
73.8
143
265
N03AF01
ATC
carbamazepine; oral, rectal
3.9
72.8
229
627
L89
ICD-10 Finland
Decubitus ulcer and pressure area
8.7
72.4
92
108
A28
ICPC
Limited function/disability NOS
2.6
71.1
462
1936
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.2
69.9
307
1041
R4110
NOMESCO Finland
Physiotherapy
2.0
66.8
944
5460
N02BF01
ATC
gabapentin; oral
2.5
66.5
458
1970
RF120, ,
NOMESCO Finland
8.4
65.5
86
105
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
64.8
62
*
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
11.2
62.5
66
60
H53.1
ICD-10 Finland
Subjective visual disturbances
2.9
62.2
326
1219
N05CF01
ATC
zopiclone; oral
1.9
62.2
1034
6301
Z43.5
ICD-10 Finland
Attention to cystostomy
20.7
61.9
47
23
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
14.2
61.4
56
40
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.0
59.2
889
5217
U04
ICPC
Incontinence urine
3.5
58.2
212
639
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
+∞
57.5
55
*
L04AX09
ATC
diroximel fumarate; oral
+∞
57.5
55
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.7
57.3
324
1260
N04BD01
ATC
selegiline; oral
8.6
56.4
72
85
36703
ICD-8 Finland
Inflammation of optic nerve and retina, Neuritis optica, retrobulbaris
147.6
55.0
58
*
N06AX16
ATC
venlafaxine; oral
2.1
52.8
644
3492
U07
ICPC
Urine symptom/complaint other
2.7
52.6
317
1271
CS494
NOMESCO Finland
Other visual field testing
4.9
52.5
118
249
A06AD11
ATC
lactulose; oral
2.4
51.0
402
1828
NA1DG
NOMESCO Finland
Cervical spine very extensive MRI examination with high intensity magnet
16.1
50.4
43
27
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
+∞
50.1
48
*
L01BB04
ATC
cladribine; systemic
+∞
50.1
48
*
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
495.4
49.5
49
*
G81.9
ICD-10 Finland
Hemiplegia, unspecified
7.1
49.2
74
106
G50.0
ICD-10 Finland
Trigeminal neuralgia
4.9
49.0
109
228
N03AF02
ATC
oxcarbazepine; oral
3.7
48.6
159
446
SPAT1216
SPAT
Assessment of functional ability
2.3
46.8
406
1920
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.3
46.4
404
1914
G04CA02
ATC
tamsulosin; oral
2.3
46.2
404
1917
4AA36, ,
NOMESCO Finland
+∞
45.9
44
*
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
11.7
43.9
45
39
J01CA08
ATC
pivmecillinam; oral
1.7
43.3
1524
11264
U08
ICPC
Urinary retention
6.5
43.0
70
109
H53.4
ICD-10 Finland
Visual field defects
5.0
43.0
93
190
SPAT1167
SPAT
Insertion of urinary catheter
5.2
43.0
89
175
J01XX05
ATC
methenamine; oral
8.4
42.8
56
68
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.2
42.4
388
1873
N30.9
ICD-10 Finland
Cystitis, unspecified
2.6
42.2
269
1106
N30.0
ICD-10 Finland
Acute cystitis
1.9
42.2
651
3798
U13
ICPC
Bladder symptom/complaint other
3.8
41.8
130
352
6BA02, ,
NOMESCO Finland
15.8
41.7
36
23
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
4.9
41.5
92
192
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
2.8
41.2
220
827
U05
ICPC
Urination problems other
3.2
41.0
172
565
G04BD10
ATC
darifenacin; oral
10.9
40.9
44
41
3419X
ICD-9 Finland
Other demyelinating diseases of central nervous system, Demyelinating disease of central nervous system, unspecified
+∞
40.7
39
*
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
5.3
40.2
82
159
R39.1
ICD-10 Finland
Other difficulties with micturition
4.0
39.6
114
292
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
74.5
39.0
44
6
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
2.8
38.8
200
738
359
Kela drug reimbursment
Mirabegroni
13.5
38.3
36
27
N18
ICPC
Paralysis/weakness
5.1
38.2
80
159
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
3.0
38.0
171
585
R32
ICD-10 Finland
Unspecified urinary incontinence
4.1
37.3
103
256
N04BC05
ATC
pramipexole; oral
2.5
37.2
242
1003
U28
ICPC
Limited function/disability (U)
8.3
37.2
49
60
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
3.9
37.1
112
297
N06AA09
ATC
amitriptyline; systemic
2.3
37.0
305
1406
N87
ICPC
Parkinsonism
7.4
36.0
52
71
119
Kela drug reimbursment
Trigeminal neuralgia or glossofaryngeusneuralgia
12.1
35.9
36
30
R42
ICD-10 Finland
Dizziness and giddiness
1.8
35.8
687
4261
RF420, ,
NOMESCO Finland
5.2
35.7
73
142
AA1AD
NOMESCO Finland
CT of head and brain
1.7
35.0
723
4577
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
6.7
34.8
55
83
M03BX02
ATC
tizanidine; oral
1.6
34.6
2123
17572
H02AB07
ATC
prednisone; oral
2.0
34.5
421
2257
N07AA02
ATC
pyridostigmine; systemic
9.4
34.5
41
44
Z3229
NOMESCO Finland
Other healthcare associate professional
2.4
32.9
250
1112
RF410, ,
NOMESCO Finland
5.5
32.9
64
119
G04BD01
ATC
emepronium; systemic
8.2
32.5
43
53
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.0
32.3
378
1995
U29
ICPC
Urinary symptom/complaint other
3.4
32.2
117
352
N06AX21
ATC
duloxetine; oral
1.9
32.0
457
2580
R15
ICD-10 Finland
Faecal incontinence
3.6
31.2
105
300
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.0
31.0
385
2073
R20.1
ICD-10 Finland
Hypoaesthesia of skin
7.0
31.0
47
68
G37.8
ICD-10 Finland
Other specified demyelinating diseases of central nervous system
+∞
30.3
29
*
RS221, ,
NOMESCO Finland
4.6
29.2
70
156
XF400
NOMESCO Finland
ECG with 12 standard connections
1.9
28.9
383
2105
Z50.1
ICD-10 Finland
Other physical therapy
2.6
28.9
176
706
G82.2
ICD-10 Finland
Paraplegia, unspecified
8.5
28.8
37
44
34109
ICD-8 Finland
Other demyelinating diseases of central nervous system, Unspecified
+∞
28.2
27
*
TPH04
NOMESCO Finland
Cathetrisation of vein
1.7
27.8
631
4068
G70.0
ICD-10 Finland
Myasthenia gravis
9.8
27.7
32
33
NA1CM
NOMESCO Finland
Cervical spine extensive MRI examination with 3 Tesla magnet
11.2
27.6
29
26
G04BE03
ATC
sildenafil; oral
5.5
27.4
53
98
A02BC02
ATC
pantoprazole; systemic
1.5
26.6
2060
17402
XX6XT
NOMESCO Finland
Other intravascular therapy with radiological guidance
8.8
26.3
33
38
G04CA01
ATC
alfuzosin; oral
2.3
26.1
216
995
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.5
25.9
1208
9184
Z93.5
ICD-10 Finland
Cystostomy status
33.3
25.5
33
10
J01XE01
ATC
nitrofurantoin; oral
3.8
25.1
77
207
A06AC01
ATC
ispaghula (psylla seeds); oral
1.6
25.1
732
5012
K59.09
ICD-10 Finland
Constipation, unspecified
2.3
25.0
191
851
Z2446
NOMESCO Finland
Social worker
2.2
24.9
223
1060
N02BF02
ATC
pregabalin; oral
2.1
24.7
251
1254
G04BE01
ATC
alprostadil; parenteral, urethral
6.1
24.2
42
70
N06AB04
ATC
citalopram; systemic
1.6
24.2
657
4418
RS222, ,
NOMESCO Finland
4.9
23.9
52
107
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
2.0
23.4
284
1512
KA1AE
NOMESCO Finland
Kidney ultrasound examination
3.5
23.3
81
237
R20.0
ICD-10 Finland
Anaesthesia of skin
5.0
23.2
50
102
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
3.6
23.2
76
214
WW400
NOMESCO Finland
Plasmaferesis
28.4
23.1
31
11
F02.89
ICD-10 Finland
Dementia in another specified disease that is classified elsewhere without information of additional symptoms
54.4
23.1
27
5
J01MA02
ATC
ciprofloxacin; systemic
1.5
22.9
1042
7832
OAB50, ,
SPAT
2.1
22.8
234
1173
H57.1
ICD-10 Finland
Ocular pain
2.3
22.8
172
762
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
2.7
22.5
122
462
XCK10
NOMESCO Finland
Photography of fundus of eye
2.1
22.2
224
1115
G20
ICD-10 Finland
Parkinson disease
3.8
22.2
67
178
H53.9
ICD-10 Finland
Visual disturbance, unspecified
2.5
22.2
140
572
R03CA02
ATC
ephedrine; oral
24.1
22.1
31
13
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
5.3
22.0
44
84
AA1BM
NOMESCO Finland
MRI examination of brain with 3 Tesla magnet
4.1
21.4
59
147
ZXY02
NOMESCO Finland
Neuropsychologist
6.0
21.2
37
62
RS121, ,
NOMESCO Finland
6.2
21.1
36
59
H30.2
ICD-10 Finland
Posterior cyclitis
8.5
21.0
27
32
H48.1
ICD-10 Finland
Retrobulbar neuritis in diseases classified elsewhere
+∞
20.9
20
*
ABD40
NOMESCO Finland
Implantation of spinal injection device
77.3
20.7
23
*
U02
ICPC
Urinary frequency/urgency
1.7
20.7
462
2948
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
3.5
20.3
71
209
ZXE21
NOMESCO Finland
Procedure duration at least 3 but less than 4 hours
5.7
20.2
37
65
ABD30
NOMESCO Finland
Implantation of spinal stimulation device
5.0
20.2
43
87
AA1AG
NOMESCO Finland
Short MRI examination of brain with median intensity magnet
3.5
20.0
69
201
SPAT1293
SPAT
Other function in accordance with rehabilitation guidance nomenclature
6.8
20.0
31
46
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.5
19.8
794
5784
G61.0
ICD-10 Finland
Guillain-Barré syndrome
8.2
19.6
26
32
SPAT1148
SPAT
Treatment of chronic ulcer or burn
1.8
19.6
286
1615
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
2.8
19.5
100
368
G04BDXX, ,
ATC
21.7
19.5
28
13
G51.0
ICD-10 Finland
Bell palsy
2.8
19.4
95
341
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.4
19.2
1066
8261
Z01.8
ICD-10 Finland
Other specified special examinations
1.5
18.9
676
4803
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.5
18.4
807
5972
SPAT1296
SPAT
Other function in accordance with occupational therapy nomenclature
4.9
18.2
40
83
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
3.2
18.2
70
219
Z2221
NOMESCO Finland
Medical doctor
1.5
18.2
835
6235
U71
ICPC
Cystitis/urinary infection other
1.9
18.0
228
1229
SPAT1262
SPAT
Handing over of treatment supplies
1.7
17.9
401
2555
N07AA03
ATC
distigmine; systemic
20.2
17.7
26
13
R4110, ,
SPAT
1.7
17.6
373
2341
RF432, ,
NOMESCO Finland
95.6
17.6
19
*
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
4.9
17.6
38
78
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
2.2
17.5
143
655
36702
ICD-8 Finland
Inflammation of optic nerve and retina, Neuritis optica. Papillitis
181.0
17.5
18
*
SPAT1222
SPAT
Counselling/guidance promoting independent living
1.7
17.4
339
2082
RS340, ,
NOMESCO Finland
14.9
17.1
28
19
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
1.9
16.8
213
1150
A49.9
ICD-10 Finland
Bacterial infection, unspecified
1.9
16.7
237
1326
M05BA04
ATC
alendronic acid; oral
2.0
16.6
174
878
R5130, ,
SPAT
15.1
16.6
27
18
R56.8
ICD-10 Finland
Other and unspecified convulsions
2.2
16.6
146
690
7819X
ICD-9 Finland
Symptoms involving nervous and musculoskeletal systems, Other symptoms involving nervous and musculoskeletal systems[SYMPTOMATA ALIA SYSTEMATIS NERVORUM ET MUSCULOSCEL]
5.1
16.5
34
67
S97
ICPC
Chronic ulcer skin
2.2
16.5
137
633
OAB43, ,
SPAT
0.7
16.3
920
11585
R47.1
ICD-10 Finland
Dysarthria and anarthria
4.9
16.1
35
72
J01MA06
ATC
norfloxacin; oral
1.6
16.1
367
2345
R60.0
ICD-10 Finland
Localized oedema
1.7
15.9
309
1895
SPAT1325
SPAT
Vaccination
1.4
15.7
773
5819
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
1.9
15.7
215
1189
N06
ICPC
Sensation disturbance other
3.7
15.7
49
134
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
2.3
15.6
124
562
3773A
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[PAPILLITIS OPTICA]
160.8
15.5
16
*
NA7CM
NOMESCO Finland
Spine and spinal cord extensive MRI examination with 3 Tesla magnet
38.2
15.4
19
5
Z73.6
ICD-10 Finland
Limitation of activities due to disability
5.2
15.3
31
60
J05AB11
ATC
valaciclovir; oral
1.6
15.3
447
3029
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
5.5
15.2
29
53
R31
ICD-10 Finland
Unspecified haematuria
1.9
15.2
194
1050
H04.10
ICD-10 Finland
Dry eye syndrome
1.6
15.2
371
2412
R27.0
ICD-10 Finland
Ataxia, unspecified
12.5
14.8
26
21
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
1.6
14.8
347
2231
CS5Z4
NOMESCO Finland
Specialised imaging for glaucoma
2.9
14.8
68
237
G37.0
ICD-10 Finland
Diffuse sclerosis
+∞
14.6
14
*
J01MA12
ATC
levofloxacin; systemic
1.5
14.6
435
2960
N03AX09
ATC
lamotrigine; oral
1.9
14.5
194
1066
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.7
14.4
278
1700
R13
ICD-10 Finland
Dysphagia
1.9
14.3
187
1020
G04BD
ATC
Drugs for urinary frequency and incontinence
17.0
14.3
22
13
K59.0
ICD-10 Finland
Constipation
2.0
14.2
147
740
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
3.5
14.2
47
134
G40.9
ICD-10 Finland
Epilepsy, unspecified
2.4
13.8
96
411
J05AB01
ATC
aciclovir; systemic
1.4
13.8
659
4921
R5599
NOMESCO Finland
Other rehabilitation service
2.5
13.6
85
347
RF122, ,
NOMESCO Finland
16.3
13.4
21
13
CS434
NOMESCO Finland
Visual field testing with Humphrey automated perimetry
2.8
13.4
68
250
N06CA01
ATC
amitriptyline and psycholeptics; systemic
1.7
13.4
265
1633
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
2.9
13.3
63
223
D12
ICPC
Constipation
2.3
13.3
97
425
KCE02
NOMESCO Finland
Transluminal endoscopic extraction of calculus from bladder
9.7
13.2
26
27
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
2.2
13.0
110
512
R30.1
ICD-10 Finland
Vesical tenesmus
2.7
13.0
68
254
TKC10, ,
SPAT
28.5
12.9
17
6
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
2.0
12.8
140
718
N06AX11
ATC
mirtazapine; oral
1.3
12.6
996
8055
G36.8
ICD-10 Finland
Other specified acute disseminated demyelination
+∞
12.5
12
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
1.7
12.5
238
1451
U99
ICPC
Urinary disease other
5.2
12.5
25
48
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
5.2
12.5
25
48
1DB07, ,
NOMESCO Finland
130.5
12.4
13
*
F05
ICPC
Visual disturbance other
2.3
12.3
95
427
G97.1
ICD-10 Finland
Other reaction to spinal and lumbar puncture
10.5
12.2
23
22
XA402
NOMESCO Finland
ENMG
2.5
12.1
77
317
H52.1
ICD-10 Finland
Myopia
1.9
12.0
145
770
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
2.5
12.0
76
313
R4130
NOMESCO Finland
Speech therapy
2.5
11.9
71
284
CA1BG
NOMESCO Finland
Eye and orbita MRI examination with high intensity magnet
5.4
11.8
23
43
G83.1
ICD-10 Finland
Monoplegia of lower limb
11.7
11.8
21
18
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
2.0
11.8
136
712
C03CA01
ATC
furosemide; systemic
1.5
11.7
463
3332
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
3.4
11.7
40
117
U01
ICPC
Dysuria/painful urination
1.6
11.5
243
1522
G04.8
ICD-10 Finland
Other encephalitis, myelitis and encephalomyelitis
+∞
11.5
11
*
T83.0
ICD-10 Finland
Mechanical complication of urinary (indwelling) catheter
35.1
11.3
14
*
N39.9
ICD-10 Finland
Disorder of urinary system, unspecified
2.8
11.2
56
205
R51.80
ICD-10 Finland
Headache
1.4
11.1
530
3941
N21.0
ICD-10 Finland
Calculus in bladder
5.3
11.1
22
42
108
Kela drug reimbursment
Myasthenia gravis
9.2
11.0
22
24
N06AX12
ATC
bupropion; oral
1.6
11.0
284
1868
SPAT1234
SPAT
Support of social functional capacity
2.0
11.0
111
555
SPAT1254
SPAT
Administration of medicine
1.5
11.0
321
2171
Y57
ICD-10 Finland
Adverse effects in the therapeutic use of other and unspecified drugs and medicaments
2.5
10.9
69
284
N02BE01
ATC
paracetamol; systemic, rectal
1.4
10.9
2716
25561
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
2.0
10.8
123
641
RS130, ,
NOMESCO Finland
8.9
10.7
22
25
KCW98
NOMESCO Finland
Other transluminal endoscopic operation on bladder
28.1
10.7
14
5
A02BA02
ATC
ranitidine; systemic
1.5
10.6
417
2991
SPAT1263
SPAT
Sampling
1.3
10.6
1156
9721
RF210, ,
NOMESCO Finland
2.2
10.6
87
401
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
1.8
10.6
159
907
OAA80, ,
SPAT
0.6
10.5
157
2644
34108
ICD-8 Finland
Other demyelinating diseases of central nervous system, Alii definiti
+∞
10.4
10
*
H20.1
ICD-10 Finland
Chronic iridocyclitis
3.3
10.4
38
116
J01MA01
ATC
ofloxacin; systemic
1.7
10.4
181
1078
G61.9
ICD-10 Finland
Inflammatory polyneuropathy, unspecified
12.1
10.3
18
15
M05BX04
ATC
denosumab; parenteral
1.9
10.3
120
631
N07AB01
ATC
carbachol; systemic
10.6
10.3
19
18
NA1BM
NOMESCO Finland
Cervical spine MRI examination with 3 Tesla magnet
9.6
10.2
20
21
AAH30
NOMESCO Finland
Thermal destruction of cranial nerve
23.4
10.2
14
6
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
2.6
10.2
58
227
ZXE10
NOMESCO Finland
More than one and less than three hours
1.3
10.1
894
7305
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
1.5
10.0
280
1873
WVA20
NOMESCO Finland
Medicine administration
2.2
10.0
79
359
G96.9
ICD-10 Finland
Disorder of central nervous system, unspecified
14.6
10.0
16
11
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
1.4
9.9
397
2857
SPAT1172
SPAT
Guidance concerning hydration
3.1
9.9
40
130
RF310, ,
NOMESCO Finland
8.7
9.8
20
23
XKW99
NOMESCO Finland
Other physiological examination of urinary or male genital system
4.5
9.8
23
51
R1250, ,
SPAT
2.2
9.7
84
396
R5140, ,
SPAT
3.2
9.7
38
121
183
Kela drug reimbursment
Lamotrigin and topiramate
3.4
9.7
34
101
N05BA01
ATC
diazepam; systemic, rectal
1.5
9.7
324
2251
ZXA10
NOMESCO Finland
Bilateral
1.4
9.6
407
2963
SPAT1301
SPAT
No procedures
1.3
9.5
745
5975
H50.52
ICD-10 Finland
Exophoria
2.7
9.5
48
177
L04AB04
ATC
adalimumab; parenteral
0.2
9.5
7
412
L95
ICPC
Osteoporosis
2.2
9.4
81
381
U72
ICPC
Urethritis
2.2
9.4
75
342
SPAT1171
SPAT
Bladder puncture
30.1
9.4
12
*
34400
ICD-8 Finland
Other cerebral paralysis, Hemiplegia NUD
21.7
9.3
13
6
D21
ICPC
Swallowing problem
2.9
9.3
43
151
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
1.3
9.3
783
6342
JC2KB
NOMESCO Finland
Functional X-ray examination of swallowing
3.3
9.3
34
104
R4120, ,
SPAT
2.9
9.3
42
146
A08
ICPC
Swelling
1.8
9.2
124
684
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
4.1
9.2
25
62
J01DB01
ATC
cefalexin; oral
1.3
9.2
2535
23748
ZY010
NOMESCO Finland
Hospital outpatient
1.7
9.2
175
1068
XF600
NOMESCO Finland
Bloodpressure measurement
1.8
9.1
142
819
N27
ICPC
Fear of neurological disease other
2.9
9.1
41
142
R5599, ,
SPAT
5.0
9.1
19
38
SPAT1260
SPAT
Consultation of another employee
1.4
9.1
424
3137
R26.0
ICD-10 Finland
Ataxic gait
11.5
9.1
16
14
RS230, ,
NOMESCO Finland
4.6
9.1
21
46
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
2.5
9.0
55
223
F32.9
ICD-10 Finland
Depressive episode, unspecified
1.4
9.0
431
3200
N02AX02
ATC
tramadol; systemic, rectal
1.3
9.0
1087
9213
RF312, ,
NOMESCO Finland
15.6
9.0
14
9
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
1.5
9.0
290
2000
N04BC04
ATC
ropinirole; oral
4.1
9.0
24
59
R47.8
ICD-10 Finland
Other and unspecified speech disturbances
3.6
8.9
29
82
N03AX14
ATC
levetiracetam; systemic
2.2
8.9
73
337
R1420, ,
SPAT
4.9
8.8
19
39
R50.9
ICD-10 Finland
Fever, unspecified
1.4
8.8
396
2909
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
1.5
8.8
329
2337
CA1CM
NOMESCO Finland
Eye and orbita extensive MRI examination with 3 Tesla magnet
8.6
8.8
18
21
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.4
8.7
524
4037
TKC20, ,
SPAT
7.2
8.7
20
28
G57.3
ICD-10 Finland
Lesion of lateral popliteal nerve
2.7
8.7
44
163
M79.2
ICD-10 Finland
Neuralgia and neuritis, unspecified
2.2
8.6
72
336
A04
ICPC
Weakness/tiredness general
1.4
8.6
434
3254
G61.8
ICD-10 Finland
Other inflammatory polyneuropathies
11.6
8.6
15
13
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
2.4
8.6
55
229
XA412
NOMESCO Finland
VEP
16.3
8.5
13
8
ZYC01
NOMESCO Finland
Remote contact by phone
1.6
8.5
182
1145
WX320
NOMESCO Finland
Spinalanesthesy
0.7
8.5
348
4719
N30.8
ICD-10 Finland
Other cystitis
3.2
8.5
33
105
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
2.3
8.5
64
286
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
2.7
8.5
44
165
WX892
NOMESCO Finland
Monitored bed care
1.7
8.5
157
952
Z02.4
ICD-10 Finland
Examination for driving licence
0.7
8.4
224
3296
A29
ICPC
General symptom/complaint other
1.4
8.4
324
2314
4AA34, ,
NOMESCO Finland
+∞
8.3
8
*
D17
ICPC
Incontinence of bowel
3.8
8.3
25
67
K07
ICPC
Swollen ankles/oedema
2.0
8.3
87
442
N05CD07
ATC
temazepam; oral
1.6
8.2
201
1305
XX9CW
NOMESCO Finland
Submitting image material and/or investigation material to patient
3.2
8.2
31
97
SPAT1255
SPAT
Intravenous administration of medicine
1.7
8.1
148
893
N86
ICD-10 Finland
Erosion and ectropion of cervix uteri
4.5
8.1
19
42
N06AB10
ATC
escitalopram; oral
1.3
8.1
678
5476
SPAT1050
SPAT
Extensive neurological examination
2.4
8.1
52
217
CA1DG
NOMESCO Finland
Eye and orbita very extensive MRI examination with high intensity magnet
11.7
8.1
14
12
H81.4
ICD-10 Finland
Vertigo of central origin
3.8
8.1
24
64
N30
ICD-10 Finland
Cystitis
1.5
8.0
267
1855
R1410
NOMESCO Finland
Drawing up a rehabilitation plan
4.1
8.0
21
51
K59.01
ICD-10 Finland
Constipation outlet obstruction type
2.7
8.0
41
153
G04AA01, ,
ATC
3.9
8.0
23
60
R2110
NOMESCO Finland
Giving the first information
1.6
7.9
208
1373
SPAT1281
SPAT
Other administrative function
1.6
7.9
193
1254
F43.21
ICD-10 Finland
Adaptation disorder with prolonged depression
2.8
7.9
38
137
XKX00
NOMESCO Finland
Pelvic floor electromyography
6.6
7.9
19
29
WX000
NOMESCO Finland
Monitoring vital functions without anesthesy
1.8
7.9
111
623
G04AC01, ,
ATC
2.0
7.8
79
397
SPAT1312
SPAT
General health counselling
1.3
7.8
838
6983
R83.4
ICD-10 Finland
Abnormal findings in cerebrospinal fluid, Abnormal immunological findings
45.1
7.7
9
*
A46
ICD-10 Finland
Erysipelas
1.5
7.7
285
2021
RF220, ,
NOMESCO Finland
2.9
7.7
34
117
S06.0
ICD-10 Finland
Concussion
1.5
7.7
279
1971
ZX198
NOMESCO Finland
Other local administration
3.4
7.7
26
76
A02BA04
ATC
nizatidine; systemic
1.7
7.7
142
862
OAA67, ,
SPAT
0.7
7.6
427
5516
S72.4
ICD-10 Finland
Fracture of lower end of femur
4.0
7.6
21
53
R1260
NOMESCO Finland
Evaluation of communicative skills
2.8
7.6
36
129
XX1XW
NOMESCO Finland
Extensive written report from radiologist
2.2
7.5
58
262
AEA00
NOMESCO Finland
Replacement of impulse generator of stimulation device in the nervous system
3.8
7.5
22
58
L98.4
ICD-10 Finland
Chronic ulcer of skin, not elsewhere classified
2.6
7.5
43
170
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
1.6
7.5
179
1158
R30.0
ICD-10 Finland
Dysuria
1.7
7.5
132
791
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
1.6
7.5
168
1071
F43.29
ICD-10 Finland
Adaptation disorder UNS
1.9
7.5
91
488
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
2.2
7.5
57
257
M48.0
ICD-10 Finland
Spinal stenosis
1.5
7.4
209
1402
SPAT1033
SPAT
Irrigation or wax removal of outer auditory canal
1.4
7.4
304
2196
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
2.4
7.4
48
201
SPAT1211
SPAT
Application of soft bandage
1.6
7.4
189
1242
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
1.6
7.4
174
1122
Z71.8
ICD-10 Finland
Other specified counselling
1.2
7.4
1041
8939
Z01.2
ICD-10 Finland
Dental examination
1.2
7.4
1446
12860
H01AA02
ATC
tetracosactide; parenteral
+∞
7.3
7
*
G37.1
ICD-10 Finland
Central demyelination of corpus callosum
+∞
7.3
7
*
3418X
ICD-9 Finland
Other demyelinating diseases of central nervous system
+∞
7.3
7
*
RS142, ,
NOMESCO Finland
6.8
7.3
17
25
M81.9
ICD-10 Finland
Osteoporosis, unspecified
1.9
7.3
89
478
H02AB06
ATC
prednisolone; systemic
1.2
7.3
1266
11115
SPAT1125
SPAT
Stoma care and guidance
3.2
7.3
28
89
G11.9
ICD-10 Finland
Hereditary ataxia, unspecified
15.8
7.2
11
7
NA7DM
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with 3 Tesla magnet
15.8
7.2
11
7
RF311, ,
NOMESCO Finland
15.8
7.2
11
7
H49.1
ICD-10 Finland
Fourth [trochlear] nerve palsy
4.3
7.2
18
42
ABD32
NOMESCO Finland
Implantation of temporary spinal stimulation device
3.7
7.2
22
60
Z74.0
ICD-10 Finland
Need for assistance due to reduced mobility
20.1
7.1
10
5
H51.8
ICD-10 Finland
Other specified disorders of binocular movement
20.1
7.1
10
5
W19
ICD-10 Finland
Unspecified fall
1.5
7.1
225
1547
R20
ICD-10 Finland
Disturbances of skin sensation
4.1
7.1
19
47
RF433, ,
NOMESCO Finland
12.0
7.1
12
10
3AX01, ,
NOMESCO Finland
5.6
7.1
19
34
F32.11
ICD-10 Finland
Moderate depressive episode with somatic syndrome
1.9
7.0
91
498
N19
ICPC
Speech disorder
3.2
7.0
27
86
N30.2
ICD-10 Finland
Other chronic cystitis
3.2
7.0
26
81
A07AA09
ATC
vancomycin; oral
2.9
6.9
32
113
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
2.9
6.9
32
113
Z10.0
ICD-10 Finland
Occupational health examination
0.7
6.9
173
2578
78050
ICD-8 Finland
Certain symptoms referable to nervous system and special senses, Vertigo
3.7
6.9
21
57
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
5.5
6.9
19
35
N39
ICD-10 Finland
Other disorders of urinary system
3.1
6.9
27
87
M05BB03
ATC
alendronic acid and colecalciferol; oral
2.6
6.8
39
154
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.2
6.8
1167
10207
CS424
NOMESCO Finland
Visual field testing with Goldmann perimetry
3.4
6.8
24
72
L29
ICPC
Musculoskeletal sympt/complt other
1.5
6.8
226
1570
A06AC51
ATC
ispaghula, combinations; oral
1.7
6.8
112
660
78161
ICD-8 Finland
Other symptoms referable to nervous system and special senses, Paraesthesia
40.1
6.8
8
*
WZC00
NOMESCO Finland
Treatment plan or consultation
1.2
6.7
1018
8787
E78.0
ICD-10 Finland
Pure hypercholesterolaemia
0.7
6.7
330
4357
WW200, ,
SPAT
1.3
6.7
734
6113
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
2.4
6.7
43
180
Z46.6
ICD-10 Finland
Fitting and adjustment of urinary device
22.6
6.7
9
*
L19
ICPC
Muscle symptom/complaint NOS
1.8
6.7
87
478
ZXE22
NOMESCO Finland
Procedure duration at least 4 but less than 5 hours
6.4
6.6
16
25
S28
ICPC
Limited function/disability (S)
4.0
6.6
18
45
SPAT1127
SPAT
Enema
5.9
6.6
17
29
S72.0
ICD-10 Finland
Fracture of neck of femur
2.2
6.6
54
251
TNX34
NOMESCO Finland
Major custom molded cast, unspecified region
2.5
6.6
39
157
KH1EE
NOMESCO Finland
Urologic ultrasound examination
6.8
6.5
15
22
Z50.5
ICD-10 Finland
Speech therapy
2.8
6.5
31
112
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
1.8
6.4
86
476
AEA30
NOMESCO Finland
Replacement of implanted pump of injection device in the nervous system
70.0
6.4
7
*
34999
ICD-8 Finland
Other diseases of spinal cord, Other and unspecified
70.0
6.4
7
*
J05AH02
ATC
oseltamivir; oral
3.2
6.4
24
75
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
1.8
6.4
92
521
M72.2
ICD-10 Finland
Plantar fascial fibromatosis
0.6
6.4
116
1857
H57.9
ICD-10 Finland
Disorder of eye and adnexa, unspecified
2.5
6.3
38
154
J01AA02
ATC
doxycycline; systemic
1.2
6.3
2237
20953
G04BE08
ATC
tadalafil; oral
9.3
6.3
12
13
QBG10
NOMESCO Finland
Excision and repair of bedsore of trunk
18.0
6.3
9
5
G04BE09
ATC
vardenafil; oral
18.0
6.3
9
5
G04.0
ICD-10 Finland
Acute disseminated encephalitis
+∞
6.3
6
*
R25.2
ICD-10 Finland
Cramp and spasm
2.0
6.2
62
311
H53.8
ICD-10 Finland
Other visual disturbances
2.4
6.2
41
174
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
2.9
6.2
28
98
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
2.1
6.2
55
265
J02AC01
ATC
fluconazole; systemic
1.2
6.1
1279
11373
EB1SA
NOMESCO Finland
Dental X-ray, bite-wing X-ray on one side of the mouth
1.2
6.1
1708
15606
N03AX11
ATC
topiramate; oral
1.8
6.1
86
484
G83.9
ICD-10 Finland
Paralytic syndrome, unspecified
7.7
6.1
13
17
PA6AG
NOMESCO Finland
Limited MRI examination of neck vasculature with high intensity magnet
3.0
6.1
26
88
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
4.1
6.1
16
39
G95.9
ICD-10 Finland
Disease of spinal cord, unspecified
8.6
6.0
12
14
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
8.6
6.0
12
14
RF214, ,
NOMESCO Finland
10.0
6.0
11
11
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
2590
14487
5.14
323.31
15.3
6.3
0.55
0.55
e9/l
0.81
2391
12679
2588
14507
5.11
320.99
15.3
6.3
0.04
0.04
e9/l
0.57
2392
12683
2446
13225
4.61
316.79
14.7
6.5
9.17
8.43
%
38.36
2399
12498
2436
13194
4.55
313.09
14.7
6.4
3.03
2.80
%
6.16
2391
12449
2430
13187
4.51
310.18
14.8
6.5
0.77
0.69
%
13.12
2384
12418
753
710
13.56
307.65
1.1
1.3
424.11
479.63
mg/l
2.38
726
679
442
167
30.55
307.65
1.0
1.1
0.96
1.04
u/l
1.54
146
70
236
51
49.88
307.65
1.0
1.0
5.16
6.08
mg/g
0.55
220
51
626
621
12.29
307.65
1.1
1.4
33.40
23.34
e6/l
0.18
472
452
541
13
500.68
307.65
3.0
1.1
—
—
—
0
0
353
177
22.29
307.65
1.1
1.1
1725.93
1483.11
miu/ml
1.83
353
177
393
160
27.86
307.65
4.2
2.1
263.48
216.71
e6/l
2.13
339
129
195
16
129.72
307.65
1.1
1.0
—
—
—
0
0
541
179
36.17
307.65
1.3
1.2
1.15
0.52
ratio
32.57
277
114
609
642
11.48
307.65
1.1
1.3
3.54
3.68
mmol/l
2.24
571
611
295
183
17.66
307.65
3.0
2.0
—
—
—
0
0
468
224
24.30
307.65
3.7
2.1
1388.40
1332.65
e6/l
0.33
412
191
675
226
37.59
307.65
1.1
1.2
56.36
32.22
mg/l
16.35
558
194
813
983
10.75
307.65
1.8
1.5
61.30
0.19
iu/ml
0.59
40
167
377
156
27.26
307.65
4.0
2.0
473.64
627.42
e6/l
1.41
316
119
660
203
40.71
307.65
1.1
1.1
—
—
—
0
0
388
36
122.52
307.65
1.2
1.1
—
—
—
0
0
664
216
38.53
307.65
1.1
1.1
215.78
223.56
mg/l
0.38
585
188
629
633
12.12
307.65
1.2
1.4
545.82
7613.08
e6/l
0.61
487
489
881
1717
6.70
307.65
3.8
1.8
1.00
1.39
g/l
9.90
867
1603
1281
2189
9.09
307.65
4.3
2.7
9.94
10.69
g/l
9.68
1199
2044
2593
14861
4.94
303.91
15.3
6.4
1.67
1.97
e9/l
14.08
2409
13333
2603
14988
4.96
302.42
15.3
6.6
0.19
0.19
e9/l
0.11
2412
13354
2454
13692
4.41
293.90
14.7
6.4
26.32
29.22
%
38.72
2414
13055
2423
13468
4.30
290.03
14.5
6.3
58.95
56.48
%
25.04
2394
12941
807
2190
4.59
274.97
2.5
2.4
28.33
19.33
au/ml
1.36
49
304
773
2034
4.69
273.87
1.3
1.3
43.85
45.40
au/ml
0.03
16
127
2616
16093
4.44
252.61
15.8
9.5
3.72
4.01
e9/l
11.55
2421
14110
1774
8968
3.20
225.25
5.7
3.1
—
1.90
—
0
11
225
208
11.56
212.17
1.1
1.3
1.67
1.91
mmol/l
5.36
210
192
1274
5522
3.17
207.60
3.8
2.5
5.02
7.18
e6/l
7.59
1198
4998
1612
8120
2.99
198.72
5.3
3.1
23.34
85.68
e6/l
2.54
1363
6039
1447
6985
2.96
191.06
5.0
2.9
0.15
0.35
e6/l
8.80
1194
4965
2152
13080
2.97
180.42
2.8
2.5
91.27
74.77
nmol/l
90.67
2045
12228
1757
9820
2.75
169.22
6.5
3.6
82.63
79.14
e6/l
0.10
1411
6619
2602
17982
3.40
165.61
9.4
4.1
2083.00
1590.62
e6/l
0.17
37
217
2245
14889
2.70
142.55
6.7
3.5
0.00
0.00
estimate
0.03
558
3060
146
129
11.81
141.33
1.1
1.4
92.39
64.07
%
2.27
23
14
2264
15121
2.70
140.91
6.7
3.6
0.00
0.01
estimate
3.56
554
2952
2249
15029
2.67
138.79
6.7
3.5
5.23
5.71
estimate
0.04
569
3099
1994
12593
2.55
138.57
17.0
10.1
0.00
0.00
e9/l
0.13
1697
10285
147
153
10.02
127.05
4.1
2.8
50.18
43.57
%
3.05
115
77
909
4287
2.57
114.31
4.7
2.6
0.98
1.18
e6/l
0.66
530
2137
104
77
13.93
112.01
1.1
1.2
6.33
18.25
%
—
21
8
395
1252
3.46
101.71
1.4
2.2
36.33
40.16
u/l
3.67
369
1151
1715
11117
2.17
98.21
4.0
4.8
37.45
36.73
g/l
6.65
1637
10491
808
3928
2.41
92.51
4.9
2.8
5.27
3.70
e6/l
1.74
422
1773
376
1270
3.22
86.83
1.4
1.4
—
—
—
0
0
356
1290
2.98
72.33
2.7
2.1
0.02
0.57
estimate
0.50
89
459
1903
13708
1.96
72.04
5.7
6.2
9.84
10.59
umol/l
3.67
1836
13082
1264
7970
1.97
70.73
7.4
3.6
0.01
0.00
estimate
0.32
550
2920
543
2511
2.40
67.43
2.5
2.0
0.05
0.02
estimate
0.37
108
580
87
118
7.55
60.69
1.1
1.7
—
—
—
0
0
81
102
8.12
60.18
1.1
1.1
37.27
263.10
ng/l
0.78
37
20
1057
6579
1.91
59.01
5.7
3.5
0.00
0.25
—
10
53
1080
6781
1.89
58.61
2.5
1.5
2.00
2.24
g/l
7.95
827
4476
668
3587
2.09
56.65
1.9
2.1
29.13
29.22
s
0.22
647
3487
1272
8589
1.80
53.37
4.3
2.7
0.06
0.07
0.03
16
133
378
1650
2.46
52.57
1.7
2.6
68.31
67.41
g/l
1.77
362
1543
454
2230
2.21
47.78
2.7
2.3
2682.51
5730.28
u/l
1.43
117
906
2462
20510
1.87
47.16
7.3
7.9
74.58
75.07
u/l
0.24
2356
19601
1560
11581
1.68
43.74
7.1
3.3
0.01
0.08
estimate
1.14
488
2527
1935
15221
1.69
43.25
4.4
4.7
6.19
6.46
mmol/l
9.08
1846
14188
1234
8670
1.69
42.22
6.2
2.9
0.00
0.14
estimate
0.75
502
2470
396
1930
2.20
42.21
4.2
2.3
0.26
0.44
e6/l
1.05
381
1827
1093
7458
1.71
41.55
2.3
2.1
138.77
193.38
u/l
1.91
1052
7128
75
138
5.54
38.95
1.0
1.1
—
—
—
0
0
98
249
4.03
34.46
1.2
1.6
—
—
—
0
0
40
44
9.19
33.02
1.0
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
62
129
4.88
28.09
1.0
1.1
—
—
—
0
0
44
68
6.55
27.27
1.0
1.1
—
—
—
0
0
2557
27788
0.60
26.63
4.2
4.4
1.49
1.49
mmol/l
0.01
2387
26495
1534
12238
1.49
25.98
5.9
6.7
1.22
1.21
mmol/l
1.94
1301
10707
2390
26345
0.63
25.68
3.6
3.8
1.24
1.26
mmol/l
0.66
2230
24979
44
73
6.10
25.46
1.0
1.1
—
—
—
0
0
44
73
6.10
25.46
1.0
1.1
—
—
—
0
0
2991
27877
2.13
24.72
17.6
13.1
20.69
20.74
mg/l
0.03
2444
22624
160
667
2.47
24.25
2.2
3.0
2.34
1.94
index
0.40
79
367
2579
27872
0.61
24.00
4.2
4.5
4.76
4.78
mmol/l
0.35
2427
26685
2606
28083
0.61
23.68
4.6
4.9
2.83
2.84
mmol/l
0.38
2432
26794
48
93
5.22
23.61
1.0
1.0
—
—
—
0
0
2884
26623
1.85
23.43
15.8
11.8
94.09
88.94
ml/min/173m2
41.42
2664
24402
563
3680
1.64
23.11
2.0
1.8
—
—
—
0
0
86
264
3.32
22.95
1.2
1.6
—
—
—
0
0
1317
10381
1.46
22.65
8.5
10.0
1.10
1.14
inr
3.60
1106
8563
41
72
5.76
22.41
1.0
1.1
—
—
—
0
0
2951
27530
1.93
21.89
16.5
13.9
3.91
3.93
mmol/l
4.85
2904
26967
38
64
6.00
21.68
1.0
1.1
—
—
—
0
0
2944
27457
1.91
21.66
16.4
13.8
139.72
139.66
mmol/l
0.78
2904
26952
27
31
8.78
21.54
1.1
1.1
91.39
44.69
%
3.22
18
13
1272
10078
1.44
20.71
4.0
3.2
29.72
30.63
u/l
0.40
1231
9593
1346
10836
1.42
19.77
5.2
6.1
1.22
1.21
mmol/l
1.68
1245
10120
902
6758
1.47
19.52
3.7
3.8
96.62
95.12
%
1.31
889
6603
41
87
4.76
18.22
1.0
1.1
—
—
—
0
0
2362
21144
1.45
18.04
4.8
3.2
42.14
39.74
u/l
0.68
2278
20298
411
2668
1.62
16.99
1.9
1.7
—
—
—
0
0
3079
29453
2.22
16.77
18.9
10.8
26.50
26.02
u/l
0.83
3037
28850
100
410
2.49
15.78
1.3
1.9
—
1548.57
—
0
14
1328
10945
1.36
15.77
2.0
2.0
96.97
98.32
pmol/l
0.45
693
5955
3076
29471
2.15
15.72
21.4
15.5
67.33
71.27
umol/l
19.21
3064
29189
22
33
6.71
14.02
1.0
1.0
—
—
—
0
0
384
2565
1.56
13.95
1.9
1.8
—
—
—
0
0
22
34
6.51
13.64
1.0
1.0
—
—
—
0
0
2628
24405
1.43
13.10
26.0
15.8
13.39
13.41
%
0.52
2609
24088
60
218
2.79
12.12
3.2
3.1
51.00
54.53
%
0.65
55
199
846
6712
1.35
12.07
1.7
1.6
19.12
20.38
nmol/l
1.87
731
5902
833
6601
1.35
11.96
7.0
3.6
1.02
1.48
kg/l
0.80
612
4320
2270
20741
1.33
11.36
3.9
4.2
10.30
10.00
mm/h
0.52
2146
19684
204
1237
1.69
10.93
1.8
1.6
—
—
—
0
0
139
759
1.87
10.64
1.6
2.1
2.62
2.92
g/l
3.35
134
706
143
790
1.85
10.56
2.0
1.8
—
—
—
0
0
144
802
1.83
10.36
1.6
2.2
9.68
11.12
mg/l
1.83
139
761
143
796
1.83
10.31
1.7
2.1
6.80
7.28
g/l
3.54
138
743
143
796
1.83
10.31
1.7
2.1
4.18
4.31
g/l
1.37
138
742
31
83
3.76
10.30
3.4
2.7
25.89
29.96
umol/l
0.86
22
62
191
1161
1.69
10.16
6.1
2.9
1.02
1.02
ratio
0.05
163
1035
142
795
1.82
10.06
1.7
2.1
3.26
3.70
g/l
4.93
137
742
2793
26493
1.43
9.99
6.1
5.5
1.70
1.77
mu/l
2.84
2641
25208
218
1381
1.62
9.87
1.2
1.3
2.66
0.93
u/ml
—
9
107
475
3549
1.40
9.62
1.7
1.7
1049.96
1184.04
nmol/l
2.12
361
2771
124
680
1.86
9.40
1.7
2.2
9.05
10.51
g/l
4.98
118
624
327
4536
0.69
9.13
1.7
1.9
3.28
3.45
ratio
1.85
236
3370
89
442
2.04
9.03
1.1
1.2
76.11
315.63
titre
—
9
32
123
692
1.81
8.62
1.7
2.3
0.29
0.89
g/l
2.39
117
616
44
166
2.67
8.38
1.7
3.0
658.09
872.07
u/ml
0.41
44
166
20
31
6.48
8.17
1.0
1.2
—
—
—
0
0
427
3223
1.37
8.07
2.5
2.7
6.05
7.00
umol/l
0.70
377
2788
1058
9042
1.25
7.95
3.5
3.0
27.40
46.75
ng/l
1.12
627
4978
83
423
1.99
7.88
1.3
1.3
—
—
—
0
0
83
423
1.99
7.88
1.3
1.3
—
—
—
0
0
106
590
1.82
7.73
1.7
2.2
0.00
0.00
g/l
-0.00
100
525
152
940
1.65
7.63
1.1
1.2
3.54
4.20
0.40
19
159
23
62
3.73
7.62
1.0
1.1
—
—
—
0
0
143
876
1.66
7.46
2.2
1.9
—
—
—
0
0
56
252
2.24
7.36
1.0
1.2
126.55
113.47
pmol/l
0.86
56
252
209
1408
1.52
7.29
1.7
2.0
3.71
7.67
iu/ml
2.76
40
355
18
29
6.24
7.23
1.0
1.1
—
—
—
0
0
22
61
3.62
7.02
1.1
1.1
—
—
—
0
0
230
1595
1.48
6.98
1.2
1.3
192.65
224.68
miu/ml
0.69
82
810
16
25
6.43
6.63
1.0
1.2
—
—
—
0
0
250
3445
0.70
6.62
1.4
1.6
3.44
3.50
mmol/l
0.33
161
2304
99
1656
0.58
6.50
1.1
1.1
1.59
1.55
g/l
0.79
99
1656
48
215
2.25
6.42
1.7
3.3
18.57
14.67
index
0.72
35
143
1024
8886
1.22
6.36
2.6
3.3
2.35
2.35
mmol/l
0.65
929
8249
2439
25583
0.80
6.18
4.9
5.3
37.01
37.88
mmol/mol
6.15
2288
24452
45
200
2.27
6.15
1.1
1.1
4.16
5.65
nmol/l
—
10
29
242
1740
1.42
6.09
2.6
2.8
63.40
72.70
e9/l
4.44
170
1248
23
73
3.17
6.01
1.3
1.2
87.13
97.49
%
0.63
23
73
712
8388
0.81
5.93
3.7
3.4
7.97
7.83
mmol/l
0.34
612
7305
13
18
7.25
5.92
1.0
1.1
—
—
—
0
0
97
1583
0.60
5.81
1.1
1.1
0.55
0.64
ratio
0.84
14
171
35
143
2.46
5.77
1.3
3.6
0.80
0.81
index
0.04
35
143
2368
24872
0.82
5.77
26.7
16.3
332.38
332.58
g/l
0.57
2360
24744
139
907
1.56
5.67
1.3
1.3
108.33
120.82
titre
0.11
18
97
330
2528
1.34
5.65
3.2
4.5
224.37
237.25
u/l
1.03
314
2414
622
5187
1.25
5.51
1.6
1.6
454.27
34428107.78
pmol/l
4.38
532
4508
12
17
7.08
5.43
1.0
1.1
—
—
—
0
0
544
4487
1.26
5.30
3.0
3.3
333.31
465.37
ng/l
0.44
311
2841
149
1003
1.51
5.29
1.8
2.0
0.23
0.23
g/l
0.45
142
948
153
1036
1.50
5.29
1.8
1.9
1.18
1.19
g/l
0.25
147
981
5
0
+∞
5.21
1.2
0.0
—
—
—
0
0
971
8516
1.20
5.20
2.4
2.6
51.15
58.71
u/l
7.23
904
7978
621
7329
0.81
5.15
4.4
4.1
7.25
9.10
mg/mmol
0.63
389
4559
15
32
4.70
4.98
1.0
1.2
—
—
—
0
0
119
775
1.56
4.94
1.8
2.3
258.95
313.47
ug/l
0.26
109
719
484
5834
0.80
4.85
1.3
1.3
3.34
8.84
u/ml
4.11
197
2452
12
22
5.47
4.60
1.6
1.6
1.48
0.90
mg/l
—
6
16
38
179
2.14
4.59
1.3
1.1
1.83
26.06
u/ml
—
6
18
136
928
1.49
4.57
4.3
5.7
1.87
1.64
%
1.09
129
873
151
1052
1.46
4.57
1.2
1.3
27.13
33.55
u/ml
—
7
62
90
1404
0.63
4.51
1.6
1.8
4.79
4.27
mg/l
0.17
58
1027
193
1412
1.39
4.46
3.9
3.1
5.15
5.13
kpa
0.13
188
1363
247
1880
1.34
4.45
3.9
3.5
1.23
1.23
mmol/l
0.32
208
1618
490
4090
1.23
4.25
2.6
3.5
0.83
0.82
mmol/l
0.59
458
3889
23
92
2.51
4.04
1.3
1.4
95.73
114.10
nmol/l
0.31
15
71
224
1707
1.34
4.03
1.8
1.6
—
—
—
0
0
76
1197
0.63
4.01
1.5
1.8
—
—
—
0
0
181
1343
1.37
3.88
4.5
3.1
133.30
131.69
g/l
0.51
174
1303
109
738
1.49
3.86
2.6
2.6
24.85
24.66
mmol/l
0.22
109
730
16
55
2.92
3.73
1.0
1.1
—
—
—
0
0
137
977
1.42
3.72
1.2
1.3
2.11
6.74
u/ml
—
8
91
72
449
1.62
3.68
1.2
1.2
—
13.07
—
0
18
46
253
1.83
3.67
1.3
1.2
—
40.40
—
0
10
137
981
1.41
3.64
1.2
1.3
2.49
8.71
u/ml
1.89
14
138
25
110
2.28
3.61
1.4
1.3
—
—
—
0
0
221
2827
0.77
3.61
1.4
1.6
1068.37
1008.64
mu/l
0.40
182
2338
47
809
0.57
3.58
1.0
1.1
1.22
1.43
u/ml
0.08
21
406
121
850
1.44
3.58
4.4
6.0
0.85
0.89
%
0.51
115
796
161
1191
1.37
3.54
4.0
3.1
1.82
1.62
mmol/l
0.35
138
873
112
779
1.45
3.50
1.2
1.3
1.59
3.12
u/ml
—
7
47
8
13
6.17
3.50
3.5
5.8
—
—
—
0
0
10
22
4.56
3.42
1.5
1.6
1.66
2.40
mg/l
—
5
14
10
22
4.56
3.42
1.5
1.6
4.64
5.19
mg/l
—
5
13
25
113
2.22
3.41
1.4
1.3
—
—
—
0
0
132
1805
0.72
3.40
1.3
1.4
—
—
—
0
0
13
347
0.37
3.40
1.8
1.4
41.17
34.15
nmol/l
0.31
13
309
286
2313
1.26
3.32
3.5
2.8
—
—
—
0
0
127
914
1.41
3.31
1.8
1.9
1.33
1.47
g/l
1.12
108
801
65
1011
0.64
3.30
1.3
1.5
52.01
60.29
ug/l
1.55
65
1011
9
19
4.75
3.23
1.0
1.1
8.44
23.00
u/l
—
9
19
776
6919
1.16
3.18
1.7
1.6
—
—
—
0
0
127
922
1.39
3.16
3.4
3.3
25.92
25.22
mmol/l
1.81
119
883
7
213
0.33
3.05
1.1
1.2
10.71
8.50
mm/h
—
7
213
29
146
2.00
3.04
1.0
1.1
—
—
—
0
0
43
720
0.59
3.00
1.0
1.1
1.65
3.19
u/ml
0.95
20
363
20
87
2.31
3.00
1.3
1.3
—
—
—
0
0
20
87
2.31
3.00
1.3
1.3
—
—
—
0
0
559
6366
0.85
2.96
1.3
1.4
19.50
23.98
iu/ml
0.45
124
1881
59
373
1.59
2.92
1.3
1.5
—
—
—
0
0
34
184
1.86
2.91
1.2
1.2
—
—
—
0
0
64
964
0.66
2.84
1.1
1.1
1.18
2.16
u/ml
0.77
30
516
47
758
0.61
2.84
1.2
1.3
—
—
—
0
0
64
416
1.55
2.83
1.0
1.1
1.49
1.49
g/l
0.03
59
382
106
763
1.40
2.81
1.8
2.0
1.22
1.74
ug/l
0.42
85
681
499
4338
1.18
2.81
2.2
2.5
14.13
14.26
umol/l
0.13
466
4062
324
2708
1.22
2.81
2.2
2.5
37.07
55.85
u/l
0.51
271
2309
89
624
1.44
2.74
1.2
1.3
—
—
—
0
0
2407
23246
1.14
2.72
5.0
4.7
14.71
14.44
pmol/l
6.56
2240
21937
93
662
1.42
2.65
1.7
1.6
—
—
—
0
0
37
620
0.59
2.63
1.0
1.1
0.01
0.21
u/ml
—
7
197
144
1863
0.76
2.62
1.4
1.4
—
—
—
0
0
51
321
1.60
2.60
1.3
1.4
—
—
—
0
0
10
30
3.34
2.60
1.0
1.1
—
—
—
0
0
83
582
1.44
2.57
2.9
3.6
25.84
42.94
mg/l
1.98
73
500
83
582
1.44
2.57
3.0
3.6
33.45
60.27
mg/l
1.32
73
499
54
818
0.65
2.50
1.0
1.1
0.17
1.12
u/ml
3.52
16
356
51
325
1.58
2.49
1.3
1.4
—
—
—
0
0
7
16
4.38
2.47
1.0
1.3
—
—
—
0
0
635
5681
1.15
2.45
2.7
2.9
644.01
860.89
ng/l
2.08
522
4691
455
3974
1.17
2.43
2.1
2.5
2.46
2.42
g/l
1.08
420
3697
112
837
1.35
2.41
1.2
1.3
64.91
37.16
u/ml
0.77
15
77
51
328
1.56
2.40
1.3
1.4
—
—
—
0
0
1100
11826
0.89
2.39
1.8
1.9
1.37
1.38
mmol/l
0.10
909
10357
48
306
1.58
2.35
1.3
1.4
—
—
—
0
0
41
253
1.63
2.30
1.8
2.1
29.00
22.23
mg/l
0.28
16
102
48
308
1.57
2.30
1.3
1.4
—
—
—
0
0
58
848
0.68
2.28
1.0
1.1
4.42
5.04
u/ml
0.12
29
472
48
309
1.56
2.27
1.3
1.4
—
—
—
0
0
101
751
1.36
2.27
4.7
3.2
25.17
24.76
mmol/l
0.88
96
698
145
1136
1.29
2.26
1.3
1.3
—
—
—
0
0
623
6911
0.88
2.26
2.0
2.4
298.59
319.08
umol/l
6.48
562
6270
745
6772
1.13
2.25
1.8
1.8
0.81
0.93
mg/l
0.97
550
5128
155
1226
1.28
2.24
1.6
1.5
—
—
—
0
0
412
3598
1.17
2.21
2.2
2.5
23.77
23.80
%
0.01
378
3362
3106
30746
1.36
2.20
32.3
20.0
6.48
6.67
e9/l
4.07
3074
30244
44
673
0.65
2.18
1.0
1.1
2.35
3.56
u/ml
0.46
16
300
3105
30737
1.35
2.18
32.2
19.9
90.89
90.45
fl
7.11
3092
30535
256
2150
1.21
2.16
4.1
3.6
5.90
5.83
kpa
0.57
249
2086
3104
30729
1.34
2.14
32.3
20.0
264.29
261.83
e9/l
1.42
3080
30302
3105
30741
1.35
2.13
32.2
20.0
4.51
4.53
e12/l
0.89
3073
30248
3105
30741
1.35
2.13
32.6
20.3
40.71
40.99
%
0.55
3092
30522
245
2053
1.21
2.12
6.7
9.6
124.92
122.67
g/l
1.14
239
2010
249
2090
1.21
2.12
4.1
3.6
2.30
1.83
mmol/l
1.54
227
1809
23
123
1.88
2.11
2.9
2.6
59.26
49.80
umol/l
0.82
23
109
26
145
1.80
2.10
1.3
1.5
132.23
132.94
nmol/l
0.02
26
145
2564
26249
0.88
2.09
4.0
4.4
5.65
5.74
mmol/l
3.82
2367
24752
71
506
1.41
2.07
2.9
2.7
8.40
8.41
kpa
0.03
71
495
9
31
2.91
2.07
1.0
1.0
—
—
—
0
0
10
37
2.71
2.07
1.0
2.2
—
—
—
0
0
3105
30749
1.34
2.05
32.4
20.1
135.76
135.74
g/l
0.02
3094
30544
368
4207
0.86
2.05
1.8
1.8
1.47
1.40
%
1.34
337
3766
50
334
1.50
2.04
1.2
1.2
—
—
—
0
0
79
577
1.38
2.01
1.2
1.2
4.79
3.30
u/ml
0.24
28
211
274
2335
1.19
1.99
2.3
2.3
0.22
0.22
g/l
0.26
262
2202
63
443
1.43
1.99
1.6
1.7
—
—
—
0
0
102
1326
0.76
1.99
1.4
1.6
—
—
—
0
0
765
7017
1.12
1.97
2.3
2.2
2.65
2.67
mg/l
0.05
655
6136
127
1000
1.28
1.95
2.3
2.1
7.50
8.97
iu/l
0.10
57
437
15
71
2.12
1.92
1.7
3.9
11.68
10.85
kpa
0.20
15
71
15
71
2.12
1.92
1.7
3.9
4.64
4.80
kpa
0.26
15
71
61
852
0.71
1.92
1.5
1.4
0.44
0.43
nmol/l
0.04
47
682
102
785
1.31
1.87
1.3
1.4
29.09
24.30
u/l
0.76
75
659
32
197
1.63
1.86
1.1
1.5
5.57
5.78
u/l
0.13
26
170
212
1778
1.21
1.85
4.2
3.0
4.82
4.66
kpa
0.43
205
1720
76
562
1.36
1.82
1.2
1.3
5.11
4.11
u/ml
0.15
27
244
84
632
1.34
1.81
2.2
2.9
—
—
—
0
0
101
781
1.30
1.80
1.2
1.3
—
—
—
0
0
61
436
1.41
1.79
2.4
2.3
17.31
16.69
%
0.99
61
426
80
601
1.34
1.75
1.2
1.5
—
—
—
0
0
25
147
1.71
1.73
1.4
1.4
20.63
17.38
u/ml
—
8
21
15
283
0.53
1.72
1.0
1.2
0.02
1.17
u/ml
—
10
143
281
2434
1.17
1.72
6.3
8.6
1.23
0.85
mmol/l
0.86
227
1987
5
13
3.85
1.71
1.2
1.1
—
—
—
0
0
41
274
1.50
1.71
1.3
1.2
—
—
—
0
0
31
481
0.64
1.70
2.3
2.6
29.45
100.51
ug/min
2.66
20
299
87
665
1.32
1.70
1.1
1.1
24.19
14.06
au/ml
0.74
21
196
44
299
1.48
1.70
1.2
1.1
—
—
—
0
0
15
75
2.00
1.69
1.0
1.9
44.00
41.66
g/l
1.10
15
75
327
2876
1.15
1.64
3.9
4.2
31.21
31.85
%
0.51
242
2080
16
83
1.93
1.64
3.0
2.2
12.21
16.07
umol/l
0.89
16
83
117
935
1.26
1.64
2.2
2.4
161.69
174.47
%
0.87
112
891
30
189
1.59
1.62
1.1
1.2
—
—
—
0
0
125
1538
0.81
1.61
1.3
1.5
1.26
1.16
ratio
0.56
71
915
42
287
1.47
1.59
1.2
1.1
—
—
—
0
0
42
287
1.47
1.59
1.2
1.1
—
—
—
0
0
127
1030
1.24
1.57
4.6
3.7
46.36
48.97
%
0.52
122
1009
126
1541
0.81
1.54
1.3
1.5
0.92
0.94
ratio
0.32
71
918
126
1541
0.81
1.54
1.3
1.5
1.18
1.19
ratio
0.06
72
923
5
15
3.34
1.52
1.2
1.1
—
—
—
0
0
125
1527
0.81
1.52
1.3
1.4
—
—
—
0
0
60
443
1.36
1.50
1.4
1.3
—
—
—
0
0
52
375
1.39
1.50
1.4
1.4
294.52
365.40
pmol/l
0.75
47
325
68
514
1.33
1.47
1.3
1.4
—
—
—
0
0
1258
13203
0.92
1.46
2.7
2.6
—
—
estimate
—
0
0
279
2451
1.15
1.45
6.4
8.6
5.06
5.09
kpa
0.31
271
2361
279
2451
1.15
1.45
6.4
8.6
12.79
13.02
kpa
0.27
271
2362
40
277
1.45
1.44
1.3
1.2
—
—
—
0
0
220
1899
1.17
1.44
5.2
8.2
6.78
8.16
mmol/l
4.18
215
1837
145
1208
1.21
1.42
6.8
11.1
16.49
16.21
%
0.60
140
1163
137
1644
0.83
1.41
1.4
1.5
66.74
60.27
ug/l
0.76
111
1358
9
178
0.50
1.39
1.2
1.3
—
—
—
0
0
68
519
1.32
1.39
3.2
3.4
1.72
2.92
ratio
0.74
33
284
60
791
0.75
1.38
2.9
3.7
586.87
1837.71
u/ml
0.45
52
681
40
561
0.71
1.37
2.1
2.7
0.89
0.89
nmol/l
0.01
29
493
6
23
2.61
1.36
3.0
2.1
—
—
—
0
0
60
452
1.33
1.35
1.6
1.6
—
—
—
0
0
185
2144
0.85
1.30
4.0
4.4
6.81
30.90
ug/l
0.86
145
1652
5
18
2.78
1.28
1.0
1.2
—
—
—
0
0
26
169
1.54
1.28
1.3
1.6
—
—
—
0
0
246
2164
1.15
1.28
6.4
9.1
95.82
96.11
%
0.25
239
2096
291
2591
1.14
1.27
6.0
5.5
—
—
—
0
0
23
146
1.58
1.25
1.3
1.5
—
—
—
0
0
339
3051
1.12
1.25
4.1
6.0
1.00
1.03
mmol/l
1.79
307
2851
37
261
1.42
1.24
1.2
1.6
—
—
—
0
0
257
2894
0.88
1.22
1.3
1.4
29.52
25.45
iu/l
1.13
228
2493
43
313
1.38
1.22
1.3
1.4
—
—
—
0
0
67
522
1.29
1.21
1.4
2.1
4.79
5.29
mmol/24h
0.77
62
474
52
391
1.34
1.21
1.4
1.3
0.67
5.06
nmol/l
0.48
52
379
2127
21792
0.93
1.21
3.5
3.6
—
—
—
0
0
20
124
1.62
1.20
1.5
2.4
7.64
8.03
mmol/l
0.14
20
124
9
170
0.53
1.18
1.6
1.5
0.54
0.50
e9/l
—
9
170
5
20
2.50
1.15
1.0
1.1
—
—
—
0
0
205
1798
1.15
1.14
2.7
3.8
64.74
79.46
ng/l
3.13
178
1613
33
233
1.42
1.13
1.2
1.7
—
—
—
0
0
149
1277
1.17
1.12
5.7
7.7
24.43
24.42
mmol/l
0.01
143
1220
25
167
1.50
1.12
3.6
1.8
2.17
1.78
u/field
0.15
12
99
842
7964
1.08
1.10
1.3
1.3
1.01
1.45
u/ml
0.87
205
2347
511
4735
1.09
1.10
2.3
2.6
2.43
2.43
mmol/l
0.20
440
4256
9
163
0.55
1.08
1.2
1.7
—
—
—
0
0
32
228
1.41
1.05
2.7
2.4
22.48
28.04
mg/l
0.31
23
159
71
572
1.25
1.02
1.5
1.6
361.68
348.99
mu/l
0.10
53
460
14
83
1.69
1.01
1.8
2.8
0.62
0.62
mmol/l
0.09
14
83
112
948
1.19
1.00
1.2
1.1
1.28
4.18
eliau/ml
2.14
13
151
68
834
0.81
0.95
1.1
1.1
—
—
—
0
0
9
51
1.77
0.94
1.2
1.1
—
—
—
0
0
6
27
2.22
0.93
1.2
1.0
—
—
—
0
0
18
118
1.53
0.90
1.2
1.3
91.50
93.41
%
—
6
51
6
29
2.07
0.89
3.0
1.9
—
—
—
0
0
9
152
0.59
0.88
1.6
2.6
28.97
223.13
ug/l
—
9
139
40
517
0.77
0.88
1.2
1.1
4.68
18166.69
iu/ml
0.54
11
129
13
79
1.65
0.88
1.1
1.1
—
—
—
0
0
44
342
1.29
0.87
1.4
1.3
0.16
0.22
nmol/l
0.47
33
259
8
44
1.82
0.85
1.0
1.0
—
—
—
0
0
12
192
0.62
0.85
1.3
1.5
5.61
5.48
mmol/l
0.14
12
185
75
625
1.20
0.83
1.3
1.6
—
—
—
0
0
8
46
1.74
0.82
2.4
2.7
5.00
5.80
ug/l
—
8
46
460
4303
1.08
0.82
4.0
4.5
1.57
1.88
ug/l
1.48
418
3948
156
1381
1.14
0.82
8.0
10.6
0.67
0.65
%
0.26
156
1373
0
24
0.00
0.79
0.0
1.0
—
—
—
0
0
68
814
0.83
0.78
1.8
3.2
1.25
1.35
mg/l
0.48
62
762
18
124
1.45
0.75
1.2
1.1
87.00
91.87
%
—
6
53
67
561
1.20
0.73
3.4
4.4
3.80
3.83
mmol/l
0.31
67
555
34
265
1.29
0.70
1.9
2.2
—
—
—
0
0
18
251
0.72
0.69
8.9
14.0
0.55
0.61
mmol/l
0.56
13
227
247
2271
1.09
0.69
3.7
3.6
4.59
4.56
pmol/l
0.12
219
2065
10
157
0.64
0.69
1.1
1.4
156.15
221.21
pmol/l
—
10
157
71
834
0.85
0.68
1.1
1.1
—
—
—
0
0
24
178
1.35
0.68
1.4
1.4
1548.18
3176.52
e6/l
1.04
17
113
5
27
1.85
0.68
1.4
2.5
1.00
0.81
u/field
—
5
27
143
1283
1.12
0.65
7.9
10.4
24.59
24.28
mmol/l
0.59
143
1263
741
7718
0.95
0.63
1.7
1.7
—
—
—
0
0
32
252
1.27
0.62
1.2
1.2
46.41
59.32
u/l
1.20
27
227
19
139
1.37
0.60
1.4
1.5
—
—
—
0
0
30
378
0.79
0.60
1.3
1.5
—
—
—
0
0
30
236
1.27
0.59
1.3
1.2
70.00
222.86
titre
—
6
42
50
596
0.84
0.59
1.3
1.7
5646.50
10017.18
e6/l
1.59
34
415
35
281
1.25
0.59
1.3
1.5
282.55
280.91
mosm/kgh2o
0.15
22
225
21
157
1.34
0.59
1.4
1.5
2179.10
72328.73
e6/l
—
10
79
0
23
0.00
0.58
0.0
1.1
—
—
—
0
0
7
113
0.62
0.58
1.1
1.1
—
—
—
0
0
13
89
1.46
0.58
3.4
2.3
—
—
—
0
0
40
328
1.22
0.57
1.9
1.7
1.65
1.68
mmol/l
0.11
40
322
58
679
0.85
0.57
1.9
2.2
3.86
4.74
umol/l
0.78
41
495
12
81
1.48
0.57
1.0
1.2
—
—
—
0
0
18
132
1.37
0.57
1.4
1.6
—
—
—
0
0
49
411
1.20
0.56
4.7
6.4
379.96
370.90
umol/l
0.14
40
365
57
485
1.18
0.56
1.2
1.5
—
—
—
0
0
11
73
1.51
0.56
2.7
4.4
—
—
—
0
0
13
90
1.45
0.55
3.7
3.4
1.23
1.25
%
0.01
13
90
193
2091
0.92
0.54
1.9
2.5
83.41
74.84
ml/min/173m2
3.00
91
851
358
3789
0.94
0.54
2.0
2.1
—
—
—
0
0
9
60
1.50
0.54
1.6
1.4
—
0.95
—
0
8
48
404
1.19
0.54
1.4
1.3
—
—
—
0
0
156
1426
1.10
0.53
7.7
10.3
1.35
1.34
%
0.07
156
1419
162
1766
0.91
0.53
1.7
1.7
316.50
288.90
mu/l
0.44
145
1580
61
526
1.16
0.52
2.3
2.1
130.47
131.10
g/l
0.08
55
416
17
226
0.75
0.52
1.2
1.2
—
—
—
0
0
6
96
0.62
0.52
1.3
1.5
11.50
8.60
ug/l
—
6
96
13
92
1.41
0.50
1.2
1.2
—
—
—
0
0
17
224
0.76
0.49
1.2
1.2
—
—
—
0
0
245
2615
0.93
0.49
2.7
2.9
0.59
0.70
ug/l
2.59
158
1440
29
355
0.82
0.48
3.7
4.9
15.93
104.19
u/ml
—
8
111
12
166
0.72
0.47
1.2
1.1
—
—
—
0
0
35
290
1.21
0.47
1.3
1.7
—
—
—
0
0
317
3000
1.06
0.47
2.1
2.2
362.68
373.33
nmol/l
0.49
292
2805
12
85
1.41
0.46
1.1
1.1
—
—
—
0
0
64
561
1.14
0.46
1.1
1.1
0.95
2.91
eliau/ml
3.90
23
291
151
1392
1.09
0.45
2.3
3.0
134.98
136.35
ng/l
0.02
129
1247
18
138
1.31
0.45
1.2
1.9
54.94
100.04
ng/l
4.87
18
138
56
638
0.88
0.42
1.2
1.4
—
—
—
0
0
6
93
0.64
0.42
1.0
1.0
8.47
44.10
iu/ml
—
6
93
0
15
0.00
0.41
0.0
1.1
—
8.09
—
0
15
74
662
1.12
0.41
1.3
1.6
—
—
—
0
0
36
305
1.18
0.40
1.1
1.1
13.29
15.08
u/ml
0.16
13
137
0
18
0.00
0.40
0.0
1.1
—
0.57
—
0
18
25
205
1.22
0.39
2.6
2.5
—
—
—
0
0
171
1598
1.07
0.39
1.5
1.5
—
—
—
0
0
32
270
1.19
0.38
1.1
1.0
—
—
—
0
0
5
36
1.39
0.38
1.0
1.0
—
—
—
0
0
44
503
0.87
0.36
1.2
1.2
—
—
—
0
0
24
198
1.21
0.36
1.2
1.3
—
—
—
0
0
1555
15781
0.97
0.35
3.2
3.3
102.09
89.72
ug/l
1.28
1472
15067
24
287
0.83
0.34
1.3
1.2
—
—
—
0
0
71
643
1.11
0.34
1.2
1.4
167.50
152.29
au/ml
0.62
16
176
30
256
1.17
0.33
3.3
2.3
32.50
32.09
pg
0.30
30
256
22
182
1.21
0.33
1.3
1.4
5.40
6.26
mmol/l
1.01
22
167
114
1227
0.93
0.33
1.2
1.3
12.70
10.62
u/l
0.82
95
1016
16
197
0.81
0.31
1.7
1.6
34.18
36.72
%
0.10
11
116
296
3084
0.96
0.30
1.9
1.9
—
—
—
0
0
119
1271
0.93
0.29
1.7
1.7
—
—
—
0
0
55
498
1.11
0.28
6.6
3.4
22.55
23.29
mg/l
0.05
39
345
541
5267
1.03
0.27
2.0
2.1
—
—
—
0
0
8
64
1.25
0.27
1.0
1.1
31.01
6.04
u/ml
—
8
64
64
698
0.92
0.27
1.2
1.2
—
—
—
0
0
16
193
0.83
0.26
3.7
3.6
—
—
—
0
0
45
405
1.11
0.26
1.3
1.7
—
—
—
0
0
9
74
1.22
0.25
1.2
1.2
—
—
—
0
0
58
531
1.09
0.25
1.1
1.1
3.56
3.24
0.08
12
106
27
236
1.15
0.24
1.0
1.1
—
—
—
0
0
17
143
1.19
0.23
1.4
2.8
321.17
177.14
umol/l
—
6
81
151
1583
0.95
0.22
2.1
2.1
6.15
7.32
ug/l
0.54
128
1411
55
597
0.92
0.22
1.9
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
9943.73
—
0
11
0
11
0.00
0.21
0.0
3.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
10.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
272.69
—
0
13
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
24
271
0.88
0.20
1.6
1.7
51.71
56.88
%
0.27
17
172
48
442
1.09
0.19
1.3
1.1
2.33
1.01
—
6
23
660
6715
0.98
0.19
2.2
2.2
—
—
—
0
0
151
1451
1.04
0.18
1.6
1.7
0.31
0.30
mg/l
0.02
67
662
288
2811
1.03
0.15
1.3
1.2
158.83
150.85
u/ml
0.12
118
1081
45
419
1.08
0.15
1.4
1.5
—
—
—
0
0
33
303
1.09
0.15
1.3
1.7
—
—
—
0
0
68
718
0.95
0.15
1.9
1.6
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
54
573
0.94
0.14
7.5
3.6
0.42
0.35
iu/ml
0.45
27
306
123
1275
0.96
0.13
1.7
1.7
21.71
11.56
u/ml
0.50
32
356
183
1882
0.97
0.13
1.8
2.8
29.98
51.58
u/ml
1.72
175
1822
158
1534
1.03
0.13
1.5
1.5
—
—
—
0
0
80
767
1.04
0.12
1.2
1.2
—
42.62
—
0
14
14
124
1.13
0.11
1.4
1.6
—
—
—
0
0
14
124
1.13
0.11
1.4
1.6
—
—
—
0
0
14
124
1.13
0.11
1.4
1.6
—
—
—
0
0
14
124
1.13
0.11
1.4
1.6
—
—
—
0
0
23
249
0.92
0.10
2.1
1.7
—
—
—
0
0
20
218
0.92
0.10
1.3
1.5
—
—
—
0
0
18
196
0.92
0.09
1.3
1.3
68.28
74.51
umol/l
0.91
18
196
36
341
1.06
0.08
1.4
1.2
—
34.29
—
0
14
589
5834
1.01
0.08
2.1
2.2
—
—
—
0
0
249
2451
1.02
0.08
1.2
1.3
164.53
184.35
u/ml
0.19
230
2290
9
85
1.06
0.07
1.1
1.2
77.33
69.42
ug/l
—
9
85
13
118
1.10
0.07
1.3
1.2
—
—
—
0
0
14
128
1.09
0.06
1.5
1.5
88.71
305.46
nmol/24h
0.50
14
128
16
148
1.08
0.06
1.1
1.5
130.38
162.51
mmol/24h
0.82
16
148
35
365
0.96
0.06
2.1
2.9
8.90
48.87
u/ml
0.63
35
360
78
763
1.02
0.05
1.5
1.4
266.39
299.64
ug/g
0.61
39
400
74
725
1.02
0.04
1.2
1.2
264.02
261.03
u/ml
0.03
42
470
32
331
0.97
0.03
1.2
1.1
—
—
—
0
0
344
3418
1.01
0.03
3.5
3.7
21.59
21.20
%
0.16
142
1351
12
112
1.07
0.03
1.2
1.7
—
—
—
0
0
12
112
1.07
0.03
1.2
1.7
—
—
—
0
0
193
1915
1.01
0.02
1.1
1.1
—
—
—
0
0
190
1891
1.01
0.01
1.9
2.3
13.03
12.39
nmol/l
0.46
175
1736
39
397
0.98
0.01
1.1
1.2
—
—
—
0
0
12
114
1.05
0.00
1.1
1.1
—
—
—
0
0
56
566
0.99
0.00
1.0
1.1
—
—
—
0
0
10
99
1.01
0.00
1.4
1.2
—
—
—
0
0
18
185
0.97
0.00
1.1
1.8
—
—
—
0
0
25
255
0.98
0.00
1.3
1.5
1.09
1.39
nmol/l
0.96
20
236
17
171
0.99
0.00
1.9
1.9
—
—
—
0
0
65
645
1.01
0.00
1.7
1.9
215.20
200.29
pmol/l
0.48
60
605
201
2015
1.00
0.00
1.5
1.4
—
—
—
0
0
455
4545
1.00
0.00
2.1
2.5
115.77
106.50
ug/g
0.25
331
3645
21
208
1.01
0.00
1.3
1.5
—
—
—
0
0
21
208
1.01
0.00
1.3
1.5
—
—
—
0
0
21
208
1.01
0.00
1.3
1.5
—
—
—
0
0
20
197
1.02
0.00
5.4
7.6
13.73
97.97
ug/l
0.51
14
130
9
94
0.96
0.00
1.7
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
7
77
0.91
0.00
1.1
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
9
94
0.96
0.00
1.7
1.7
—
—
—
0
0
9
94
0.96
0.00
1.7
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
5.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
26.94
—
0
9
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
6
67
0.90
-0.00
1.0
1.0
75.57
74.91
ug/l
—
6
56
Mortality – FinRegistry
↥Association
Association between endpoint G6_MS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MS | 1.952 [1.74, 2.19] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.613 |
During the follow-up period (1.1.1998 — 31.12.2019), 690 out of 8943 females with G6_MS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MS | 1.862 [1.65, 2.1] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.015 |
During the follow-up period (1.1.1998 — 31.12.2019), 583 out of 4008 males with G6_MS died.
Mortality risk
Mortality risk for people of age
years, who have G6_MS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.221% | 0.428% |
| 5 | 1.32% | 2.309% |
| 10 | 3.478% | 5.606% |
| 15 | 6.353% | 10.683% |
| 20 | 10.966% | 17.637% |
Relationships between endpoints
↥Index endpoint: G6_MS – MS-disease / Multiple Sclerosis
GWS hits: 14
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data